SCHEMBL858299

SCHEMBL858299

Cc1ncnc(N2CCOc3ccc(-c4cnc(N)cn4)cc3C2)c1Cc1ccc(F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 4/20 0.36
PRKDC P78527 1/20 0.35
KIT P10721 3/20 0.33
PIK3CA P42336 3/20 0.33
CREBBP Q92793 4/20 0.33
AURKA O14965 1/20 0.33
FLT1 P17948 1/20 0.33
GCK P35557 1/20 0.33
FLT4 P35916 1/20 0.33
MAP3K11 Q16584 1/20 0.33
STK17A Q9UEE5 1/20 0.33
TNIK Q9UKE5 1/20 0.33
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
STK4 Q13043 1/20 0.33
STK3 Q13188 1/20 0.33
LRRK2 Q5S007 1/20 0.33
GPR142 Q7Z601 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3802990 0.90 PRKDC (0.44) RPS6KB1PRKDCKITPIK3CATNIK
SCHEMBL856838 0.89 SLC6A2 (0.36) RPS6KB1PRKDCKITPIK3CASTK4
SCHEMBL3759082 0.88 RPS6KB1 (0.36) RPS6KB1PRKDCKITPIK3CACREBBP
SCHEMBL856184 0.88 PIK3CA (0.38) RPS6KB1PRKDCKITPIK3CAGPR142
SCHEMBL3802501 0.86 KIT (0.38) RPS6KB1PRKDCKITLRRK2GPR142
SCHEMBL859239 0.85 RPS6KB1 (0.36) RPS6KB1PRKDCKITPIK3CAAURKA
SCHEMBL858284 0.85 GRIA1 (0.37) RPS6KB1PRKDCKITPIK3CACREBBP
SCHEMBL861453 0.85 GPR142 (0.34) RPS6KB1PRKDCKITGPR142
SCHEMBL3722126 0.85 LRRK2 (0.35) RPS6KB1KITPIK3CACREBBPSTK4
SCHEMBL3755389 0.84 GRM5 (0.39) RPS6KB1PRKDCPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US claimed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA RPS6KB1 32/4885PRKDC 2737/4885KIT 224/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA RPS6KB1 32/4885PRKDC 2431/4885KIT 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.